Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Determinants of HIV-related survival among Texas prison inmates.
AIDS Patient Care STDS. 1999 Jun;13(6):355-61. Unique Identifier : AIDSLINE MED/20301673 Baillargeon J; Borucki M; Williamson J; Dunn K; Department of Internal Medicine, University of Texas Medical; Branch, Galveston, USA. baillargeon@uthscsa.edu
Abstract:
Research indicates that being incarcerated adversely affects disease progression and overall health status. Because HIV infection is a growing problem among prison populations in the United States, understanding how incarceration affects HIV-related survival patterns is critical. The present study examined determinants of HIV-related survival in a cohort of 2380 Texas Department of Criminal Justice (TDCJ) inmates who were treated for HIV/AIDS, dating from January 1, 1992 and June 31, 1997. Assessment of the study factors indicated that there were no substantial violations of the assumptions of the Cox's proportional hazards (PH) model in the present study population. Furthermore, to address the potential problem of censoring-related bias, mortality information was collected on all inmates who were paroled on the basis of disease status. The present study's findings indicate that the following factors were associated with significant decreases in HIV-related survival in the TDCJ prison population: male gender, older age, self-report of no known HIV transmission risk factors, and presence of cytomegalovirus (CMV), Mycobacterium avium complex (MAC), and Pneumocystis carinii pneumonia. Moreover, survival decreased in a monotonic fashion with decrease in baseline CD4 count. While the majority of the present study's findings were consistent with those reported for non-incarcerated populations, it will be important for investigators to assess whether these findings persist among future cohorts of prison inmates.
Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/DIAGNOSIS/DRUG THERAPY/ MORTALITY Adult Anti-HIV Agents/ADMINISTRATION & DOSAGE Cohort Studies Confidence Intervals Female Human HIV Infections/DIAGNOSIS/DRUG THERAPY/*MORTALITY Male Middle Age Prisoners/*STATISTICS & NUMER DATA Prisons Proportional Hazards Models Survival Analysis Texas/EPIDEMIOLOGY
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
